{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:51Z","timestamp":1793774811363,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.anai.2023.02.022","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T02:15:52Z","timestamp":1677636952000},"page":"768-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource\u00a0utilization"],"prefix":"10.1016","volume":"130","author":[{"given":"Jeremiah","family":"Hwee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert W.","family":"Jakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Baylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sheng Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13601-019-0277-4","article-title":"Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm","volume":"9","author":"Leru","year":"2019","journal-title":"Clin Transl Allergy"},{"issue":"11","key":"10.1016\/j.anai.2023.02.022_bib0003","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.02.022_bib0005","unstructured":"EMA. EU\/3\/04\/213: Orphan Designation for the Treatment of Hypereosinophilic Syndrome. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu304213. Accessed May 14, 2022."},{"key":"10.1016\/j.anai.2023.02.022_bib0006","unstructured":"Orphanet. Prevalence and Incidence of Rare Diseases: bibliographic data. Available at: https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. Accessed September 15, 2022."},{"issue":"4","key":"10.1016\/j.anai.2023.02.022_bib0007","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/iid3.495","article-title":"The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom","volume":"9","author":"Requena","year":"2021","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.anai.2023.02.022_bib0009","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2009.07599.x","article-title":"The hypereosinophilic syndromes: current concepts and treatments","volume":"145","author":"Gleich","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.anai.2023.02.022_bib0010","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.02.022_bib0011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.anai.2023.02.022_bib0012","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ehm.12.14","article-title":"Clinical management of the hypereosinophilic syndromes","volume":"5","author":"Cogan","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.anai.2023.02.022_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.iac.2015.05.006","article-title":"Management of hypereosinophilic syndromes","volume":"35","author":"Roufosse","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.anai.2023.02.022_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","article-title":"Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes","volume":"13","author":"Dispenza","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"10.1016\/j.anai.2023.02.022_bib0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.23588","article-title":"Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome","volume":"89","author":"Helbig","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.anai.2023.02.022_bib0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JAA.S40244","article-title":"Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases","volume":"8","author":"Menzella","year":"2015","journal-title":"J Asthma Allergy"},{"issue":"8","key":"10.1016\/j.anai.2023.02.022_bib0018","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anai.2023.02.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.02.022_bib0020","unstructured":"EMA. Mepolizumab (Nucala) summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf. Accessed October 6, 2022."},{"issue":"6","key":"10.1016\/j.anai.2023.02.022_bib0021","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.02.022_bib0022","unstructured":"Medefield. America Inc. GreenBook directory. Available at: https:\/\/www.greenbook.org\/company\/Medefield-America-Inc. Accessed August 18, 2022."},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2019.08.005","article-title":"Approach to patients with eosinophilia","volume":"104","author":"Kuang","year":"2020","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.anai.2023.02.022_bib0024","unstructured":"American Academy of Allergy, Asthma and Immunology. Hypereosinophilic syndrome. Available at: https:\/\/www.aaaai.org\/conditions-and-treatments\/related-conditions\/hypereosinophilic-syndrome. Accessed August 3, 2022."},{"issue":"6","key":"10.1016\/j.anai.2023.02.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02248-2018","article-title":"Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series","volume":"53","author":"Tab\u00e8ze","year":"2019","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2023.02.022_bib0026","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.mayocp.2016.11.018","article-title":"38-year-old man with asthma and eosinophilia","volume":"92","author":"Andersen","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/07853890.2021.2014555","article-title":"Clinical analysis of hypereosinophilic syndrome first presenting with asthma-like symptoms","volume":"54","author":"Wei","year":"2022","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.anai.2023.02.022_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s42358-021-00223-2","article-title":"Factors associated with anxiety and depression in rheumatoid arthritis patients: a cross-sectional study","volume":"61","author":"Uda","year":"2021","journal-title":"Adv Rheumatol"},{"issue":"9","key":"10.1016\/j.anai.2023.02.022_bib0029","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"Klion AD. How I treat hypereosinophilic syndromes","volume":"126","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anai.2023.02.022_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.02.022_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2017-000209","article-title":"Monitoring long-term oral corticosteroids","volume":"6","author":"Mundell","year":"2017","journal-title":"BMJ Open Qual"},{"issue":"4","key":"10.1016\/j.anai.2023.02.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.02.022_bib0033","doi-asserted-by":"crossref","first-page":"14009","DOI":"10.1038\/npjpcrm.2014.9","article-title":"Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey","volume":"24","author":"Price","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.anai.2023.02.022_bib34","series-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"Dolgin","year":"1994"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:31:51Z","timestamp":1761053511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1081120623001291"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.02.022","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource\u00a0utilization","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}